Thermo Fisher Scientific Opens $90 Million Viral Vector Manufacturing Site in Lexington

Thermo Fisher Scientific has officially opened its new $90 million viral vector CDMO (contract development and manufacturing organization) site in Lexington. The 50,000-square-foot facility will add more than 200 jobs and support the development, testing and manufacture of viral vectors, which are critical to advancing new life-saving gene and cell therapies globally.

Earlier this year, Thermo Fisher completed the acquisition of Brammer Bio, adding this leading viral vector CDMO to its Pharma Services business. The new Lexington site provides much-needed capacity for viral vector development and manufacturing, which to date has been a bottleneck for biotech companies. This investment is part of a larger strategy to accelerate commercialization of new therapies by providing a range of services – from drug development through clinical trials to commercial manufacturing – to support pharma and biotech companies of all sizes.

The Lexington viral vector CDMO site will be supported by a diverse workforce of scientists, quality control specialists and production teams. These employees will use specialized, Good Manufacturing Practices (GMP) in a state-of-the-art laboratory to produce, test and manufacture viral vectors. With the addition of the Lexington site, Thermo Fisher now has more than 2,500 employees at 15 facilities supporting various businesses in the Commonwealth. (Source: Thermo Fisher Scientific Website, 12 December, 2019)